When the neutrophil count is too low, it is known as neutropenia. Typically, a low neutrophil count (neutropenia) results in ...

Q4 2024 Management View CEO Paula Ragan highlighted 2024 as a transformative year for X4 Pharmaceuticals, with the U.S. approval and launch of XOLREMDI (mavorixafor) for WHIM syndrome, a rare ...

X4 Pharmaceuticals announced that its Phase 3 4WARD trial for chronic neutropenia is now active at around 90% of targeted sites, with expected full enrollment by Q3 or Q4 of 2025 and top-line data ...

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and an important dose-limiting toxicity in cancer treatment. The incidence of severe ...

Neutropenia in individuals with a congenital defect or patients with cancer who are undergoing chemotherapy is generally treated with granulocyte colony-stimulating factor (G-CSF) to restore ...